Mechanisms of neurodegenerative disorders. Part 1: Protein aggregates

Archives of Neurology

Volumn 57, Issue 6, 2000, Pages 793-796

  Wolozin, Benjamin ^a   Behl, Christian ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MELATONIN; PROTEINASE INHIBITOR; VACCINE;

CLINICAL TRIAL; DEGENERATIVE DISEASE; HUMAN; IMMUNIZATION; MOLECULAR GENETICS; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 0034123691     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.6.793     Document Type: Review

References (19)

1. Jarrett J, Lansbury P. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055-1058.
2. Suzuki N, Cheung T, Cai X, et al. An increased percentage of long amyloid-β protein secreted by familial amyloid-β protein precursor (BAPP717) mutants. Science. 1994;264:1336-13340.
3. Blacker D, Wilcox M, Laird N, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357-360.
4. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261:921-923.
5. Bales K, Verina T, Dodel R. et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet. 1997;17:263-264.
6. Du Y, Ni B, Glinn M, et al. α2-Macroglobulin as a β-amyloid peptide-binding plasma protein. J Neurochem. 1997;69:299-305.
7. Conway K, Harper J, Lansbury P. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318-1320.
8. Hashimoto M, Hu LJ, Xia Y, et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport. 1999;10:717-721.
9. Ostrerova N, Petrucelli L, Farrer M, et al. α-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci. 1999;19:5782-5791.
10. Atwood C, Moir R, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273:12817-12826.
11. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998; 282:1914-1917.
12. DeArmond S, Prusiner S. Molecular neuropathology of Prion diseases. In: Rosenberg R, Prusiner S, DiMauro S, Barchi R, eds. The Molecular and Genetic Basis of Neurological Disease. 2 ed. Boston, Mass: Butterworth-Heinemann; 1997: 145-163.
13. Scherzinger E, Lurz R, Turmaine M, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997; 90:549-558.
14. Behl C, Davis J, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid-β protein toxicity. Cell. 1994;77:817-827.
15. Yan S, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685-591.
16. McGeer PL, McGeer EG. Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann N Y Acad Sci. 1996;777:213-220.
17. Schenk D Barbour R, Dunn W, et al. Immunization with amyloid-attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-178.
18. Vassar R, Bennett B, Babu-Khan S, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735-741.
19. Soto C, Sigurdsson E, Morelli L, Kumar R, Castano E, Frangione B. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998;4:822-826.